Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma
M Ladetto, G Pagliano, S Ferrero, F Cavallo… - Journal of Clinical …, 2010 - ascopubs.org
Purpose We investigated the effect on minimal residual disease, by qualitative and real-time
quantitative polymerase chain reaction (RQ-PCR), of a consolidation regimen that included …
quantitative polymerase chain reaction (RQ-PCR), of a consolidation regimen that included …
Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma
M Ladetto, G Pagliano, S Ferrero… - Journal of Clinical …, 2010 - research.uniupo.it
Purpose: We investigated the effect on minimal residual disease, by qualitative and real-time
quantitative polymerase chain reaction (RQ-PCR), of a consolidation regimen that included …
quantitative polymerase chain reaction (RQ-PCR), of a consolidation regimen that included …
[引用][C] Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted …
M Ladetto, G Pagliano, S Ferrero, F Cavallo… - JOURNAL OF …, 2010 - ricerca.uniba.it
Major tumor shrinking and persistent molecular remissions after consolidation with
bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma IRIS …
bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma IRIS …
Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma
M Ladetto, G Pagliano, S Ferrero… - Journal of clinical …, 2010 - pubmed.ncbi.nlm.nih.gov
PURPOSE We investigated the effect on minimal residual disease, by qualitative and real-
time quantitative polymerase chain reaction (RQ-PCR), of a consolidation regimen that …
time quantitative polymerase chain reaction (RQ-PCR), of a consolidation regimen that …
[引用][C] Major Tumor Shrinking and Persistent Molecular Remissions After Consolidation With Bortezomib, Thalidomide, and Dexamethasone in Patients With …
M Ladetto, GT Pagliano, S Ferrero, F Cavallo… - JOURNAL OF …, 2010 - iris.uniupo.it
Major Tumor Shrinking and Persistent Molecular Remissions After Consolidation With
Bortezomib, Thalidomide, and Dexamethasone in Patients With Autografted Myeloma IRIS …
Bortezomib, Thalidomide, and Dexamethasone in Patients With Autografted Myeloma IRIS …
Major Tumor Shrinking and Persistent Molecular Remissions After Consolidation With Bortezomib, Thalidomide, and Dexamethasone in Patients With Autografted …
M Ladetto, G Pagliano, S Ferrero, F Cavallo… - Journal of Clinical …, 2010 - cir.nii.ac.jp
< jats: sec>< jats: title> Purpose</jats: title>< jats: p> We investigated the effect on minimal
residual disease, by qualitative and real-time quantitative polymerase chain reaction (RQ …
residual disease, by qualitative and real-time quantitative polymerase chain reaction (RQ …
Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma …
M Ladetto, G Pagliano, S Ferrero, F Cavallo… - Journal of Clinical …, 2010 - europepmc.org
PURPOSE We investigated the effect on minimal residual disease, by qualitative and real-
time quantitative polymerase chain reaction (RQ-PCR), of a consolidation regimen that …
time quantitative polymerase chain reaction (RQ-PCR), of a consolidation regimen that …
Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma
M Ladetto, G Pagliano, S Ferrero, F Cavallo… - JOURNAL OF …, 2010 - iris.unito.it
PURPOSE We investigated the effect on minimal residual disease, by qualitative and real-
time quantitative polymerase chain reaction (RQ-PCR), of a consolidation regimen that …
time quantitative polymerase chain reaction (RQ-PCR), of a consolidation regimen that …
Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma
M Ladetto, G Pagliano, S Ferrero… - JOURNAL OF …, 2010 - research.unipg.it
PURPOSE We investigated the effect on minimal residual disease, by qualitative and real-
time quantitative polymerase chain reaction (RQ-PCR), of a consolidation regimen that …
time quantitative polymerase chain reaction (RQ-PCR), of a consolidation regimen that …
Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma
M Ladetto, G Pagliano, S Ferrero… - Journal of Clinical …, 2010 - research.uniupo.it
Purpose: We investigated the effect on minimal residual disease, by qualitative and real-time
quantitative polymerase chain reaction (RQ-PCR), of a consolidation regimen that included …
quantitative polymerase chain reaction (RQ-PCR), of a consolidation regimen that included …